Interview with Anil Raghavan, Country Head – India, Quintiles India
Quintiles first established its operations in India in 1997, which was a very early stage in clinical research. What have been the main changes undergone by the country since then?…
Address: GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030, India
Tel: +91 22 24959595
Web: http://www.gsk-india.com/
Established in the year 1924 in India GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3500 people. Globally, we are a USD 45 billion, leading, research-based healthcare and pharmaceutical company. In India, we are one of the market leaders with a turnover of Rs. 2003 crore and a share of 5.0%*. At GSK, our mission is to improve the quality of life by enabling people to do more, feel better and live longer. This mission drives us to make a real difference to the lives of millions of people with our commitment to effective healthcare solutions.
The GSK India product portfolio includes prescription medicines and vaccines. Our prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The company is the market leader in most of the therapeutic categories in which it operates. GSK also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer and others.
With opportunities in India opening up, GSK India is aligning itself with the parent company in areas such as clinical trials, clinical data management, global pack management, sourcing raw material and support for business processes including analytics.
GSK’s best-in-class field force, backed by a nation-wide network of stockists, ensures that the Company’s products are readily available across the nation. GSK has two manufacturing units in India, located at Nashik and Thane as well as a clinical development centre in Bangalore. The state of art plant at Nashik makes formulations while bulk drugs and the active pharmaceutical ingredients are manufactured at Thane.
Being a leader brings responsibility towards the communities in which we operate. At GSK, we have a Corporate Social Responsibility program that works towards fulfilling basic healthcare, education and other developmental needs of the underserved population. With this dedication and commitment, we believe that the world will be better, healthier and happier.
GSK is committed to developing new and effective healthcare solutions. The values on which the group was founded have always inspired growth and will continue to do so in times to come.
* [Source: ORG IMS Indian Purchase Audit (IIPA), Sept MAT 2010]
GSK India
• In India, GSK is one of the market leaders with a turnover of Rs. 2003 crore and a share of 5.0 percent
[source: IMS Indian Purchase Audit (IIPA), Sept MAT 2010]
• GSK leads in several therapeutic segments – dermatology, anti-helmentics, hormones
[source: IIPA,Sept MAT 2010]
• GSK has 7 products in the top 50 brands, and the top five GSK products are Augmentin, Calpol, Ceftum, Phexin, and Betnesol
[source: IIPA, Sept MAT 2010]
• GSK’s vaccines division is ranked first in a fast-growing vaccines market. Some leading products in India are Havrix, Varilrix,Rotarix,Hiberix and Cervarix
[source: Vaccines audit June MAT 2010]
• GSK India’s R&D centres at Thane and Nashik have been granted recognition by the Department of Scientific and Industrial Research, Government of India
• The number of clinical studies conducted in India is rapidly growing across a range of therapy areas
• GSK India’s social responsibility programmes focus on development of under developed villages, women, children and aged, specifically in the areas of healthcare and education
Quintiles first established its operations in India in 1997, which was a very early stage in clinical research. What have been the main changes undergone by the country since then?…
Right after you started heading the India operations roughly 15 years ago, you had to oversee one the biggest mergers in the industry at that time. How challenging was that…
While we have seen many MNCs becoming increasingly interested in India, the story of Nycomed has been quite unique. Rather than starting off with marketing and sales offices, India was…
Two weeks ago, Lupin announced its annual results, portraying 6 years of sustained growth and a net profit up by 27%. How pleased were you with this performance, and were…
Compared to 5 years ago, MNCs have increased their presence in India. Some even have become market leaders, particularly through acquisitions of domestic players. How is this redistributing the game…
If we first take a step back and look at how Bharat Biotech was established, we see quite a remarkable story. It is rather exceptional to see scientists becoming entrepreneurs.…
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
While your appointment as Managing Director was not a long time ago, you immediately faced the big task to oversee one of the most complicated corporate mergers the local Indian…
One trend we have seen taking place over the years is that, today, Indian machines are far better in quality and in par with international standards, than 15 years ago.…
PwC is undoubtedly renowned for its strong network of international expertise, but every market still has its own particularities… What is it, that your clients struggle with the most in…
Undeniably, the landscape for CROs has dramatically changed compared to when you started in the 1990s. The idea of having India as a clinical research destination was not mature yet…
There is no doubt that India has become a country of rising opportunities. Can you first elaborate how important India has become for the Group worldwide? India has become very…
See our Cookie Privacy Policy Here
